15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Nurix Therapeutics Inc, 13 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $25.00 to $45.00, a moderate spread. The average target of $34.58 sits 48% above the current $23.42. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.54 next quarter toward $-2.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy13100%
Hold00%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Nurix Therapeutics Inc.
As of Jul, 13 of 13 firms rate NRIX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NRIX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.54
Range $-0.77 – $-0.17 · 10 analysts · -34% YoY
Next period, 10 analysts expect Nurix Therapeutics Inc to earn $-0.54 a share (range $-0.77 – $-0.17), versus $-0.82 a year earlier. Full-year consensus is $-2.72, growing to $-2.15 the year after.
REVENUE · NEXT QUARTER
$23.3M
Range $9.0M – $40.0M · 10 analysts · +72% YoY
Revenue is expected to reach $23.3M (range $9.0M – $40.0M), +71.7% year-over-year. Full-year consensus is $57.7M, rising to $96.4M next year.
Top analysts covering Nurix Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NRIX.
#1
Joel Beatty
Baird · Rank #111
Buy
$33.00+40.9% to target
Overall win rate
46%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$34.00+45.2% to target
Overall win rate
38%
+ Follow
#3
Joseph Catanzaro
Piper Sandler · Rank #219
Buy
$35.00+49.4% to target
Overall win rate
41%
+ Follow
#4
Gil Blum
Needham · Rank #298
Buy
$34.00+45.2% to target
Overall win rate
24%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #311
Buy
$33.00+40.9% to target
Overall win rate
25%
+ Follow
NRIX stock forecast FAQ
What is NRIX's average 12-month price target?+
The 12 analysts with a live target average $34.58 for Nurix Therapeutics Inc over the next 12 months, ranging from a $45.00 high to a $25.00 low.
Is NRIX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 13 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NRIX?+
The Street-high target is $45.00 (Jefferies), and the Street-low is $25.00 (Wells Fargo). The average of all 12 active targets is $34.58.
How many Wall Street analysts cover NRIX?+
13 analysts have an active rating on Nurix Therapeutics Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering NRIX?+
Among analysts who currently cover NRIX, Joel Beatty of Baird has the strongest overall Quantellect track record (Rank #111). Their current call is Buy with a $33.00 target.
What is Nurix Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.54 per share (range $-0.77 – $-0.17) across 10 analysts. Full-year EPS is projected at $-2.72, rising to $-2.15 the following year.
How much revenue is Nurix Therapeutics Inc expected to report next quarter?+
Consensus revenue is $23.3M (range $9.0M – $40.0M). Full-year revenue is projected at $57.7M, growing to $96.4M next year.
Have analysts been upgrading or downgrading NRIX lately?+
As of Jul, 13 of 13 firms rate NRIX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NRIX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
